Trending at Lumira Ventures

Lumira Portfolio Company, G1 Therapeutics, Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer

Altamash Hashmi G1 Therapeutics, Portfolio News

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™ (trilaciclib) administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in …

Lumira portfolio company, G1 Therapeutics, Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)

Altamash Hashmi G1 Therapeutics, Portfolio News

– PRESERVE 2 Will Evaluate Survival Benefit of COSELA in 250 Patients with Locally Advanced Unresectable or Metastatic TNBC RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …

G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer

Altamash Hashmi G1 Therapeutics, Portfolio News

– Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Laboratory Values, and Use of Supportive Care Interventions – – Compared with Placebo, Administering COSELA Prior …

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Abi Kumar G1 Therapeutics, Portfolio News

COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy – Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, …

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Abi Kumar G1 Therapeutics, Portfolio News

Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions RESEARCH TRIANGLE PARK, N.C. and RIDGEFIELD, Conn., March 02, 2021 …

G1 Therapeutics Reports Q3 2019 Financials

Jennifer Schram G1 Therapeutics, Portfolio News

RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2019. Review the full filling here. “Based on written feedback from the FDA following our pre-NDA meeting …

Trial Results Show Trilaciclib Decreases Myelosuppression in Extensive-Stage Small Cell Lung Cancer (SCLC) Patients

Jennifer Schram G1 Therapeutics, Portfolio News

This global, randomized, double-blind, placebo-controlled, multicenter, Phase 2 study (NCT03041311) assessed the potential of trilaciclib to reduce the incidence and consequences of chemotherapy-induced myelosuppression in patients with newly diagnosed extensive-stage small-cell lung cancer (ES-SCLC) treated with etoposide, carboplatin and atezolizumab …

G1 Therapeutics presents data from Phase 2 mTNBC trial for trilaciclib at ESMO19

Jennifer Schram G1 Therapeutics, Portfolio News

RESEARCH TRIANGLE PARK, N.C. and BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported preliminary overall survival (OS) data from the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy for the treatment of metastatic …

FDA Grants G1 Therapeutics Breakthrough Therapy Designation & Provides Q2 2019 Financial Update

Jennifer Schram G1 Therapeutics, Portfolio News

Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2019. …